

AMENDMENTS TO THE CLAIMS

Claims 1-14 (Cancelled)

15. (Previously Presented) A compound which is 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-
{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-
dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof.
16. (Previously Presented) A compound which is 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-
{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-
dihydropyridine-3-carboxamide.
17. (Previously Presented) A compound which is a pharmaceutically acceptable salt of 6-
methyl-5-(1-methyl-1H-pyrazol-5-yl)-N- {[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-
oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide.
18. (Previously Presented) A pharmaceutical formulation comprising a compound, as defined
in any one of Claims 15 to 17 in admixture with a pharmaceutically acceptable diluent or
carrier.